## **Core Concept**
Entacapone is a medication used in the management of Parkinson's disease. It belongs to a class of drugs known as **catechol-O-methyltransferase (COMT) inhibitors**. The primary goal of using entacapone in Parkinson's disease is to enhance the effectiveness of levodopa, a precursor to dopamine, which is deficient in Parkinson's disease.

## **Why the Correct Answer is Right**
Entacapone works by inhibiting the enzyme **catechol-O-methyltransferase (COMT)**, which breaks down levodopa. By preventing this breakdown, entacapone increases the availability of levodopa in the central nervous system, thereby increasing dopamine levels and improving symptoms of Parkinson's disease. This mechanism makes entacapone particularly useful when used in conjunction with levodopa/carbidopa therapy, as it helps to prolong the therapeutic effects of levodopa.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because it does not accurately describe the mechanism or benefit of entacapone in the context of levodopa/carbidopa treatment.
- **Option B:** This option is incorrect as it does not relate to the known effects or mechanism of action of entacapone.
- **Option C:** While not provided, any option that does not accurately reflect the COMT inhibition mechanism and its benefits in increasing levodopa availability and efficacy is incorrect.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that entacapone and other COMT inhibitors are specifically used to prevent the peripheral conversion of levodopa to 3-O-methyldopa, thereby increasing levodopa's bioavailability and half-life. This can lead to smoother, more sustained dopaminergic stimulation and potentially improved motor control in patients with Parkinson's disease.

## **Correct Answer:** C. Entacapone inhibits the enzyme catechol-O-methyltransferase (COMT), which breaks down levodopa, thereby increasing its availability and effectiveness when used with levodopa/carbidopa.